Sapient leverages NULISA panels and assays to capture subtle changes in the low-abundance portion of the proteome, including cytokines, chemokines, and neuroinflammatory mediators.
Sapient is a Certified Service Provider for Alamar Biosciences’ NULISA panels on the ARGO™ HT System. These assays complement and extend our mass spectrometry-based targeted proteomics services by enabling detection of hard-to-assay cytokines, chemokines, and neuroinflammatory mediators in biofluid samples.
The NULISA platform uses a proprietary sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ligation assays by over a thousand-fold to attomolar levels – allowing for highly quantitative measures of low-abundance proteins that are not amenable to mass spectrometry measure.
Detects 120+ biomarkers of CNS disease, including
neuro-specific proteins.
Measures 120+ cytokines & chemokines from less than 25 μL of sample input.
Through NULISA panels and assays, Sapient can provide highly quantitative measures of low-abundance proteins that are important modulators of immune processes. This complements our mass spectrometry-based (MS) proteomics in several ways by enabling:
Sapient is additionally working closely with Alamar to offer NULISAseq assays under regulated guidance, including CAP/CLIA and GCLP – further extending our multi-omics services for clinical development.
With attomolar sensitivity and 12 logs of dynamic range, the NULISAseq Inflammation Panel 250 profiles 250+ biomarkers of inflammation and immune response from a single 25 μl sample, including low-abundance cytokines such as IL4, IL5, IL17, and IL33. It offers unmatched detectability of the most relevant cytokine and chemokine inflammation targets in blood-based and CSF biofluids.
Sapient also offers the the NULISAseq Inflammation Panel AQ for absolute quantification of 150+ of these key protein biomarkers. With 99% quantifiability in normal samples, this panel allows for detection of subtle changes related to disease progression or therapeutic response.
Sapient houses the Alamar ARGO HT instrument in our discovery lab to perform NULISAseq analyses.
This panel provides best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins associated with neurodegenerative disorders in plasma and CSF.
The panel includes important proteins such as p-tau217, GFAP, NfL, and alpha- synuclein and enables measure of changes in key inflammatory pathways, supporting protein biomarker discovery and validation for CNS diseases. Results are highly reproducible, with median CV <10%, even at multiplexing scale.
Designed specifically for mouse and murine experiments, this panel encompasses 120 proteins selected for their involvement in inflammation, neurodegeneration, and oncogenesis.
The multiplexed panel detects and quantifies cytokines, chemokines, and immune-related and neurology-focused proteins, such as p-tau217, using less than 25 μL of sample input. It is ideal for investigating disease pathophysiology or the efficacy of novel interventions in preclinical models, generating maximal insight from minimal sample.
The NULISAseq Mouse Panel 120 offers the most comprehensive coverage of protein biomarkers in mouse models supporting preclinical and translational research.
Sapient also offers NULISAqpcr single-plex assays with qPCR readout as well as custom development of bespoke assays for your key low-abundance proteins of interest.
Tap our deep expertise in assay development and NULISA technologies to obtain robust measures for difficult-to-assay cytokines, chemokines, and inflammatory mediators.
A first-of-its-kind offering for CNS disease research, this single-plex solution is setting a new benchmark for absolute quantitation of the phosphorylated tau 217 (pTau217) isoform originating specifically from the central nervous system using as little as 10 µL of plasma, serum, dried blood spots, or CSF sample.
Learn about Alamar’s novel NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) and how it enables:
For questions or to discuss a specific project, we encourage you to book a time to talk to our scientific team.
"*" indicates required fields
